loading page

Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children
  • +9
  • Nicole Ullrich,
  • Sanjay Prabhu,
  • Roger Packer,
  • Stewart Goldman,
  • Nathan Robison,
  • Jeffrey Allen,
  • David Viskochil,
  • David Gutmann,
  • John Perentesis,
  • Bruce Korf,
  • Michael Fisher,
  • Mark Kieran
Nicole Ullrich
Children's Hospital Boston

Corresponding Author:[email protected]

Author Profile
Sanjay Prabhu
Boston Children's Hospital
Author Profile
Roger Packer
Children's National Health System
Author Profile
Stewart Goldman
Ann & Robert H Lurie Children's Hospital of Chicago
Author Profile
Nathan Robison
Children's Hospital Los Angeles, University of Southern California Keck School of Medicine
Author Profile
Jeffrey Allen
NYU Langone Health
Author Profile
David Viskochil
University of Utah
Author Profile
David Gutmann
Washington University in Saint Louis School of Medicine
Author Profile
John Perentesis
Childrens Hospital Medical Center
Author Profile
Bruce Korf
University of Alabama at Birmingham
Author Profile
Michael Fisher
Children's Hospital of Philadelphia
Author Profile
Mark Kieran
Dana-Farber Cancer Institute
Author Profile


Data for visual acuity (VA) after treatment of neurofibromatosis type 1-associated optic pathway gliomas (NF1-OPGs) is limited. We retrospectively collected VA, converted to logMAR, before and after targeted therapy with everolimus for NF1-OPG, and compared to radiologic outcomes (14/18 with NF1-OPG, 25 eyes [3 without quantifiable vision]). Upon completion of treatment, VA was stable in 19 eyes, improved in 4 eyes, and worse in 2 eyes; visual and radiologic outcome were discordant. In summary, the majority of children with NF1-OPG exhibited stabilization of their VA after everolimus treatment. A larger, prospective study will help delineate visual outcomes after targeted therapy.
09 Oct 2020Submitted to Pediatric Blood & Cancer
09 Oct 2020Submission Checks Completed
09 Oct 2020Assigned to Editor
13 Oct 2020Reviewer(s) Assigned
09 Nov 2020Review(s) Completed, Editorial Evaluation Pending
10 Nov 2020Editorial Decision: Revise Minor
11 Nov 20201st Revision Received
11 Nov 2020Submission Checks Completed
11 Nov 2020Assigned to Editor
12 Nov 2020Review(s) Completed, Editorial Evaluation Pending
12 Nov 2020Editorial Decision: Accept
18 Dec 2020Published in Pediatric Blood & Cancer. 10.1002/pbc.28833